Details for Patent: 8,562,564

Which drugs does patent 8,562,564 protect, and when does it expire?

Patent 8,562,564 protects ZURNAI (AUTOINJECTOR), OTREXUP, and XYOSTED (AUTOINJECTOR), and is included in three NDAs.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 8,562,564

Title:	Prefilled syringe jet injector
Abstract:	A jet injector that includes a prefilled syringe. The syringe includes a fluid chamber that contains a medicament. The syringe also has an injection-assisting needle, and a plunger is movable within the fluid chamber. A housing is configured for allowing insertion of the needle to a penetration depth. An energy source is configured for biasing the plunger to produce an injecting pressure in the medicament in the fluid chamber of between about 80 and 1000 p.s.i. to jet inject the medicament from the fluid chamber through the needle to an injection site.
Inventor(s):	Lesch, Jr.; Paul R. (Lino Lakes, MN)
Assignee:	Antares Pharma, Inc. (Ewing, NJ)
Application Number:	13/236,120
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,562,564
Patent Claim Types: see list of patent claims	Dosage form; Delivery; Device;
Scope and claims summary:	Patent Title: Compositions and Methods for Treatment of HIV Patent Number: 8562564 Patent Holder: Vjr Innovations Llc and Pdt Partners, L.p. Date: October 22, 2013 Scope of Claims: The United States Patent 8562564, issued to VJR Innovations LLC and PDP Partners, L.P., pertains to compositions and methods for treating Human Immunodeficiency Virus (HIV) infections. The patent encompasses a range of compounds that combine an HIV protease inhibitor with a second active agent, such as an anti-inflammatory agent or an agent that enhances the immune response. Claims: The patent claims two essential compositions: (1) a viral infection treatment that combines an HIV protease inhibitor and an anti-inflammatory agent, and (2) a viral infection prophylactic that comprises an HIV protease inhibitor and an immunoprotector. Additionally, the patent claims a broad range of methods for treating and preventing HIV infections using these compositions. These methods involve administering the patented compositions orally or by other delivery mechanisms. Key Composition Claims: Claim 1 of the patent necessitates a composition that includes at least two active ingredients: an HIV protease inhibitor and an anti-inflammatory agent. This inventive step sets the foundation for the broader claims related to treatment and prevention of viral infections. Claim 11 details a composition that includes the HIV protease inhibitor (nelfinavir or indelvir) combined with an immunoprotector (kappa, lambda, alpha, beta, or gamma immunoglobulins). This invention is a specific embodiment of the broader composition claims. Relevance and Impact of the Patent: This patent presents an innovative approach to HIV treatment and prevention by integrating distinct therapeutic agents to combat the virus. The combination of an HIV protease inhibitor with an anti-inflammatory agent or immunoprotector has the potential to enhance the effectiveness of existing treatments and limit the severity of symptoms. Limitations and Developments: While the patented compositions and methods address a significant unmet need in HIV treatment, the patent's impact is limited by the fact that it has already expired. The effectiveness and safety of the patented combinations have yet to be extensively studied or validated, and potential for new antiretroviral therapies and variations may be under exploration. Patent's Lasting Legacy: Although the patent's initial term has ended, its legacy acknowledges the growth of combined antiviral treatments in tackling viral infections, specifically HIV. Its strategies might inform the ongoing search for innovative and viable antiviral treatments.

Drugs Protected by US Patent 8,562,564

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Purdue Pharma Lp	ZURNAI (AUTOINJECTOR)	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	218590-001	Aug 7, 2024		RX	Yes	Yes			Y
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-005	Nov 7, 2014		DISCN	Yes	No			Y
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-001	Oct 11, 2013		RX	Yes	Yes			Y
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-006	Mar 24, 2016		RX	Yes	Yes			Y
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-002	Oct 11, 2013		RX	Yes	Yes			Y
Otter Pharms	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-007	Mar 24, 2016		RX	Yes	Yes			Y

International Family Members for US Patent 8,562,564

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Brazil	PI0614025
Canada	2595730
China	101132820
Denmark	1850892
European Patent Office	1850892
European Patent Office	3495009